Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Tuesday, September 29, 2009

2006 paper : FMO3 'in action'

FMO3 is always of great interest to the blog, since it is one of the group of 'xenobiotic metabolizing enzymes' that deal with both external (xenobiotic) and internal compounds, either to neutralize for excretion or to 'activate' if needed in the main circulation. All the xenobiotic metabolizing enzymes are suspects in metabolic body odor, but FMO3 in particular since it is known to cause trimethylaminuria and also deals with 1,000s of smelly sulfide, amine and phosporous containing compounds.

In this 2006 paper, it looks as if this was the first time that FMO3 was finally 'seen in action' (i.e. it is finally demonstrated how it oxidizes a compound ... the reaction). Most readers know that the enzyme is dependent on vitamin B2 (riboflavin, as part of the FAD), but this paper explains in depth that it is also dependent on NADPH which itself uses niacin (vitamin B3) as a cofactor. This does not mean that niacin is likely to be of any benefit, and niacin itself can cause quite an undesirable symptom when taken as a supplement (the niacin flush, as well as a feeling of unease). There has been mention of cases where the FMO3 enzyme 'failure' is at the NADPH stage, but for the moment it is not known if this is of any significance.

Full paper 2006 : Mechanism of action of a flavin-containing monooxygenase

Interesting quotes from the paper :

Elimination of nonnutritional and insoluble compounds is a critical task for any living organism. Flavin-containing monooxygenases (FMOs) attach an oxygen atom to the insoluble nucleophilic compounds to increase solubility and thereby increase excretion...

... Flavin-containing monooxygenases (FMOs) and cytochromes P450 are two important microsomal (i.e. liver) proteins involved in the process of nonnutritional foreign compounds metabolism known as xenobiotics. Their main function is to add molecular oxygen to lipophilic compounds, making them soluble to ensure rapid excretion. FMOs oxygenate nucleophilic O, N, S, and Se atoms of a wide range of substrates, such as amines, amides, thiols, and sulfides...

...The mammalian FMO gene family contains five similar genes (FMO1 through FMO5). FMO1 and FMO3 are prominent isoforms expressed mainly in liver microsomes and in other tissues. FMO1 expression is higher in fetal liver, whereas FMO3 is more abundant in adult human. FMO2 is expressed in the lungs of nonhuman primates; FMO4 and FMO5 represent scarce isoforms (5, 6). Individuals with defective FMOs exhibit “fish odor syndrome” caused by excretion of trimethylamine instead of its oxygenated form, trimethylamine N-oxide in urine, sweat, and breath...

...Cytochrome P450s contain heme as a prosthetic group, whereas FMOs use FAD. These proteins need a cofactor NADPH in addition to the prosthetic group to accomplish their functional goal...

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory, the New York Structural Biology Center, and SGX Pharmaceuticals, Inc., have determined the atomic crystal structure and functional mechanism of an enzyme essential for eliminating unwanted, non-nutritional compounds such as drugs, industrial chemicals, and toxic compounds from the body...

..."For FMOs, the end result -- that an oxygen atom gets added to make these compounds soluble -- is simple," Swaminathan says...

...People with defective FMOs might also suffer additional side effects from drugs, industrial compounds, or other chemicals.


Post a Comment